Entry Point Capital, LLC Anavex Life Sciences Corp. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding AVXL
# of Institutions
155Shares Held
27.3MCall Options Held
515KPut Options Held
838K-
Black Rock Inc. New York, NY6.39MShares$55.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$40.9 Million0.0% of portfolio
-
State Street Corp Boston, MA3.07MShares$26.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$16.3 Million0.0% of portfolio
-
Wealthgarden F.S. LLC El Segundo, CA910KShares$7.86 Million0.32% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $673M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...